Creates global cell and gene therapy manufacturing services platform
Today it is official that Cobra Biologics has been aquired by Cognate BioServices.
This deal brings together Cognate’s expertise in cell and cell-mediated gene therapy product manufacture with Sweden’s world leading manufacturing services for plasmid DNA and viral vectors. This is great news for the ATMP field marking a CDMO with full focus on life cycle management of cell and gene therapy products to address the growing demand for rapid access to advanced manufacturing capabilities integrated into a commercial-scale manufacturing environment.
Peter Coleman, CEO of Cobra Biologics, says, “Cobra Biologics has built its reputation in providing high quality process development, manufacturing and fill/finish services for plasmid DNA, viral vector, and proteins. Joining forces with Cognate is exciting, positioning the combined Cognate-Cobra as a leading service provider across the advanced therapy supply chain. The acquisition by Cognate will strengthen Cobra’s capability and capacity, broadening our service offering for both new and existing customers.”
Cognate provides a broad range of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies, including clinical and commercial development in mid to late stage clinical trials and product scale-up into commercial manufacturing. These services have successfully developed autologous and allogeneic products across multiple cell-based technology platforms from start to finish. Combining with Cobra’s DNA and viral manufacturing, in leading international GMP approved facilities in Sweden and the UK, this CDMO now has the expertise and geographical footprint to dominate commercial ATMP manufacture.
The deal is backed by EW Healthcare Partners.
See press release here; https://www.cognatebioservices.com/cognate-bioservices-announces-acquisition-of-cobra-biologics/